Acadia Healthcare adds Daniel Cancelmi to board
Acadia Healthcare Company, Inc. announced board changes involving the retirement of one director and the appointment of another experienced healthcare finance executive.
Rhea-AI Filing Summary
Acadia Healthcare Company, Inc. announced board changes involving the retirement of one director and the appointment of another experienced healthcare finance executive. Wade D. Miquelon will retire from the Board at the 2026 annual meeting and will not stand for re-election, with the company stating his decision did not result from any disagreement regarding operations, policies or practices.
The Board expanded from 10 to 11 members and appointed Daniel Cancelmi as a Class III director and member of the Audit Committee, effective immediately, with his term running until the 2026 annual meeting. Following Mr. Miquelon’s retirement, the Board size will revert to 10 members as the number of Class III directors decreases from four to three. The company highlighted Mr. Cancelmi’s long-tenured leadership at Tenet Healthcare and broader healthcare finance experience, and noted there are no special appointment arrangements, family relationships or related-party transactions requiring disclosure.
Positive
- None.
Negative
- None.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board changes did Acadia Healthcare (ACHC) disclose in this 8-K filing?
Who is Daniel Cancelmi and what role will he have at Acadia Healthcare (ACHC)?
Did Wade Miquelon’s retirement from Acadia Healthcare’s board involve any disagreement with the company?
How will Acadia Healthcare’s board size change following these director moves?
How will Daniel Cancelmi be compensated for his service on Acadia Healthcare’s board?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. |
Retirement of Mr. Miquelon from the Board of Directors
On March 9, 2026, Wade Miquelon informed the Board of Directors (the “Board”) of Acadia Healthcare Company, Inc. (the “Company”) of his decision to retire as a director of the Company, effective at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Accordingly, Mr. Miquelon will not stand for reelection to the Board at the 2026 Annual Meeting. His decision was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.
Appointment of Dan Cancelmi to the Board of Directors
On March 12, 2026, the Board increased the size of the Board from 10 to 11 members by increasing the number of Class III directors serving on the Board from three to four and appointed Daniel Cancelmi to serve as a Class III director on the Board, effective immediately. The term of office of Class III directors expires at the 2026 Annual Meeting, when the number of Class III directors will decrease from four to three with Mr. Miquelon’s retirement. Mr. Cancelmi will serve as a member of the Audit Committee of the Board.
Mr. Cancelmi will receive compensation for his service to the Company in accordance with the Company’s existing compensation plan for non-employee directors. Information with respect to the director compensation plan is set forth in the definitive proxy statement for the Company’s 2025 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 10, 2025.
There are no arrangements or understandings between Mr. Cancelmi and any other person pursuant to which Mr. Cancelmi was appointed to the Board as a director, nor are there any family relationships between Mr. Cancelmi, on the one hand, and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer, on the other hand. Mr. Cancelmi is not a party to any transaction or relationship with the Company and its subsidiaries that require disclosure under Item 404(a) of Regulation S-K.
On March 12, 2026, in connection with the foregoing retirement and appointment, the Board approved a reduction in the size of the Board from 11 to 10 members by decreasing the size of Class III of the Board by one member, effective upon Mr. Miquelon’s retirement in connection with the 2026 Annual Meeting.
| Item 7.01 | Regulation FD Disclosure. |
On March 12, 2026, Acadia issued a press release announcing the foregoing matters. The press release is furnished herewith as Exhibit 99.1 hereto and is incorporated herein by reference.
The information furnished pursuant to Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit |
Description | |
| 99.1 | Press Release of Acadia Healthcare Company, Inc., dated March 12, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ACADIA HEALTHCARE COMPANY, INC. | ||||||
| Date: March 12, 2026 | By: | /s/ Brian Farley | ||||
| Brian Farley | ||||||
| Executive Vice President, Secretary and General Counsel | ||||||
Exhibit 99.1
FOR IMMEDIATE RELEASE
Acadia Healthcare Appoints Daniel Cancelmi to Board of Directors
Wade D. Miquelon to Retire from the Board at Upcoming Annual Meeting
FRANKLIN, Tenn. – March 12, 2026 – Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (“Acadia”) today announced that it has appointed Daniel Cancelmi to its Board of Directors, effective immediately.
Mr. Cancelmi is a seasoned finance leader with an expansive knowledge of health care and a proven track record of driving superior financial performance. Most recently, he served as Executive Vice President and Chief Financial Offer of Tenet Healthcare Corporation, where he played a significant role in the company’s transformation and in strengthening its balance sheet. Over the course of his three-decade career at Tenet, he held a range of finance roles of increasing responsibility, including oversight of both enterprise-wide and hospital-level financial operations.
“We are pleased to welcome Dan to our Board and look forward to benefitting from his significant financial leadership expertise and decades of healthcare services experience,” said Reeve B. Waud, Chairman of Acadia’s Board of Directors. “Acadia remains focused on executing its strategy to spur disciplined growth by expanding access to essential, evidence-based behavioral healthcare, improving clinical outcomes and driving operational efficiency across its national network. Dan’s perspective will be critical as we continue advancing our priorities with a focus on driving value creation for all shareholders.”
Mr. Cancelmi was selected following a comprehensive search process, led by the Board’s Nominating and Corporate Governance Committee with the assistance of a nationally recognized executive search firm and following constructive engagement with Khrom Capital.
The Company also announced today that director Wade D. Miquelon has decided not to stand for re-election at the 2026 Annual Meeting.
Mr. Waud continued, “We are grateful to Wade for his many contributions to the company. Wade has dedicated significant time and energy over his years of service, and Acadia is better for it. He has been a key voice in helping to guide Acadia as it expanded access to care for those who need it most. We look forward to continuing to benefit from his strategic insights through his planned retirement as we continue to evaluate all paths to deliver enhanced shareholder value.”
Goldman Sachs and J.P. Morgan are serving as financial advisors and Kirkland & Ellis LLP is serving as legal advisor to the Company.
About Daniel Cancelmi
Daniel Cancelmi brings more than 30 years of healthcare finance and operational leadership experience. He most recently served as Executive Vice President and Chief Financial Officer of Tenet Healthcare Corporation, where he oversaw all aspects of the company’s finance organization. During his more than 11-year tenure as CFO, Mr. Cancelmi was instrumental in transforming Tenet’s performance, growing revenue to nearly $21 billion in 2023 and producing a strong balance sheet. As CFO of Tenet, Mr. Cancelmi also helped oversee the Company’s portfolio transformation into a diversified healthcare services company, including its acquisitions of United Surgical Partners International (USPI) and ownership interests in over 100 ambulatory surgery centers from SurgCenter Development (SCD), as well as various hospital divestitures. Mr. Cancelmi previously held a series of senior finance and accounting leadership roles of increasing responsibility at Tenet, including SVP and controller and principal accounting officer. He began his career at PricewaterhouseCoopers. He holds a Bachelor of Science from Duquesne University and is a member of its Board of Directors. Mr. Cancelmi is a certified public accountant licensed in Texas and Florida.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of December 31, 2025, Acadia operated a network of 277 behavioral healthcare facilities with over 12,500 beds in 40 states and Puerto Rico. With approximately 25,000 employees serving more than 84,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Description of Business
Unless the context otherwise requires, all references herein to “Acadia,” “the Company,” “we,” “us” or “our” mean Acadia Healthcare Company, Inc. and its consolidated subsidiaries. Acadia Healthcare Company, Inc. is a holding company whose direct and indirect subsidiaries own and operate acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers, residential treatment centers and facilities providing outpatient behavioral healthcare services to serve the behavioral healthcare and recovery needs of communities throughout the U.S. and Puerto Rico. The terms “facilities,” “centers,” “clinics,” and “hospitals” refer to entities owned, operated, or managed by subsidiaries of Acadia Healthcare Company, Inc. References herein to “employees” refer to employees of subsidiaries of Acadia Healthcare Company, Inc.
Forward-Looking Information
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements related to our strategy, growth, anticipated operating results for future periods and our share repurchase program. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from government and commercial payors, including because of the significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act (“OBBBA”) enacted on July 4, 2025; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) changes in expectations resulting from actuarial and other reviews of our liability reserves and other aspects of our business; (vi) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vii) potential disruptions to our information technology systems or a cybersecurity incident; and (viii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes, including, without limitation, due to OBBBA’s introduction of work or community engagement requirements in the Medicaid expansion population; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia’s periodic reports and other filings with the Securities and Exchange Commission.
Media:
Adam Pollack / Mahmoud Siddig / Thomas Crosson
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
apollack@joelefrank.com / msiddig@joelefrank.com / tcrosson@joelefrank.com
Investors:
Patrick Feeley
Senior Vice President, Investor Relations
(615) 861-6000
Patrick.Feeley@acadiahealthcare.com